Who
Matthew L. Kaplan
Director
Company insider
Files Form 4 as: Director, Nuvectis Pharma.
In numbers
- Trades disclosed
- 9
- Buys
- 2
- Sells
- 0
- Bought
- $115K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 1 Apr 2022
- Last trade
- 11 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 12 Jun 2026 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 5 Nov 2025filed 6 Nov 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $64K11,000 at $5.84 | filing |
| 12 Jun 2025filed 12 Jun 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 13 Jun 2024filed 13 Jun 2024 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 16 Jun 2023filed 20 Jun 2023 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 12 May 2022filed 16 May 2022 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $19K1,177 at $15.96 | filing |
| 12 May 2022filed 16 May 2022 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $32K1,823 at $17.47 | filing |
| 1 Apr 2022filed 5 Apr 2022 | NVCT Nuvectis Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
News
Nuvectis Pharma (NASDAQ:NVCT) Stock Falls 6.8% – Here's WhyNVCT · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Matthew L. Kaplan; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.